Prescriber beware: It is ill-advised to administer compounded sincalide
SNMMI SMARTBRIEF | OCT 09, 2013
Because of the current unavailability of Kinevac, the form of sincalide for injection approved by the FDA, nuclear medicine clinics may consider alternatives, including purchasing a compounded product, and some pharmacists may be considering compounding this drug. However, several concerns relative to compounded sincalide make such practices ill-advised. Learn more.
No comments:
Post a Comment